Sugi Predict

Sugi Predict / Compounds / SCHEMBL472402

SCHEMBL472402

SCHEMBL472402

N#Cc1ccc(C(F)(F)F)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.53
▸ KIF11 P52732 2/20 0.51
▸ SLC22A12 Q96S37 2/20 0.50
▸ PDK1 Q15118 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK3 Q15120 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ FAAH O00519 4/20 0.43
▸ AR P10275 5/20 0.41
▸ VCAM1 P19320 1/20 0.41
▸ HSD11B1 P28845 1/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ CNR2 P34972 1/20 0.39
▸ MRGPRX4 Q96LA9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30899301 1.00 TRPV4 (0.53) TRPV4KIF11SLC22A12PDK1PDK2
SCHEMBL8576403 0.86 TRPV4 (0.44) TRPV4KIF11SLC22A12PDK1PDK2
SCHEMBL628094 0.84 TRPV4 (0.57) TRPV4KIF11SLC22A12PDK1PDK2
SCHEMBL7569957 0.81 TRPV4 (0.58) TRPV4KIF11SLC22A12PDK2AR
SCHEMBL12203355 0.80 PDK1 (0.43) TRPV4KIF11SLC22A12PDK1PDK2
SCHEMBL10766551 0.80 KDR (0.40) TRPV4KIF11SLC22A12PDK1FAAH
SCHEMBL1727083 0.78 KIF11 (0.73) TRPV4KIF11SLC22A12AR
SCHEMBL5203682 0.78 KIF11 (0.53) TRPV4KIF11SLC22A12AR
SCHEMBL30168580 0.78 KIF11 (0.73) TRPV4KIF11SLC22A12AR
SCHEMBL7374120 0.77 PDK1 (0.48) TRPV4KIF11SLC22A12PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117915903-A Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof 佛罗里达大学研究基金会公司 2024-04-19 — — CN disclosed
US-20240124466-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE 2024-04-18 — — US disclosed
EP-4259118-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS The Scripps Research Institute (US) 2023-10-18 — — EP disclosed
WO-2022125989-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SCRIPPS RESEARCH INSTITUTE, THE (US) 2022-06-16 — — WO disclosed
CN-107001332-B Piperidine derivatives 豪夫迈·罗氏有限公司 2020-05-15 — — CN disclosed
US-20190307737-A1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2019-10-10 — — US disclosed
EP-3227282-B1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-03 — — EP disclosed
US-10172843-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2019-01-08 — — US disclosed
EP-3227282-A1 NOVEL PIPERIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-10-11 — — EP disclosed
US-20170266175-A1 NOVEL PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-09-21 — — US disclosed
US-20150259326-A1 NOVEL THERAPEUTICS FOR BRAIN CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-09-17 — — US disclosed
WO-2013188813-A2 NOVEL THERAPEUTICS FOR BRAIN CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-12-19 — — WO disclosed
EP-2412372-A1 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases Abbott Laboratories (US) 2012-02-01 — — EP disclosed
US-7998993-B2 TRPV1 antagonists ABBOTT LABORATORIES (US) 2011-08-16 — — US disclosed
EP-2220059-B1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LAB (US) 2011-08-03 — — EP disclosed
CN-101835762-A 2-aminooxazole derivatives as TRPV antagonists useful for the treatment of pain ABBOTT LAB 2010-09-15 — — CN disclosed
EP-2220059-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN Abbott Laboratories (US) 2010-08-25 — — EP disclosed
US-20090124666-A1 TRPV1 ANTAGONISTS ABBOTT LABORATORIES (US) 2009-05-14 — — US disclosed
WO-2009055749-A1 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN ABBOTT LABORATORIES (US) 2009-04-30 — — WO disclosed
US-4238617-A FROM HYDRAZINE, AN AMINE AND A NITRILE ROHM AND HAAS COMPANY (US) 1980-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150259326-A1 NOVEL THERAPEUTICS FOR BRAIN CANCER ING2, GMFG, PLP2 TRPV4 4775/4885KIF11 1137/4885SLC22A12 1945/4885
US-20190307737-A1 NOVEL PIPERIDINE DERIVATIVES ADORA1, ADRA1D, ADORA2B TRPV4 177/4885KIF11 2755/4885SLC22A12 1984/4885
US-20170266175-A1 NOVEL PIPERIDINE DERIVATIVES ADORA1, ADRA1D, ADORA2B TRPV4 177/4885KIF11 2755/4885SLC22A12 1984/4885
US-20090124666-A1 TRPV1 ANTAGONISTS TRPV1, TRPV2, TRPV3 TRPV4 4/4885KIF11 4072/4885SLC22A12 543/4885
US-10172843-B2 Piperidine derivatives ADRA1D, ADORA1, ADRA1A TRPV4 435/4885KIF11 2771/4885SLC22A12 2673/4885
US-20240124466-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SNCA, NLN, HTT TRPV4 4602/4885KIF11 2156/4885SLC22A12 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.